Graphite Bio JPM presentation video
January 11, 2021 Graphite Bio JPM presentation video
Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID
rajeshl2021-01-13T13:57:07+00:00January 13, 2021 Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID REDWOOD CITY, Calif. January 13, 2021 -- Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Graphite Bio, Inc., a next-generation gene editing company focused on therapies that harness targeted gene integration...
Graphite Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
rajeshl2021-01-09T02:12:10+00:00January 8, 2021 Graphite Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., January 8, 2021 – Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that Josh Lehrer, M.Phil, M.D., chief executive officer, will present an overview of Graphite...
Graphite Bio Appoints Pharmaceutical Industry Veterans to Board of Directors
rajeshl2020-12-21T13:36:39+00:00December 21, 2020 Graphite Bio Appoints Pharmaceutical Industry Veterans to Board of Directors - Joseph Jimenez, former CEO of Novartis, joins Board as an independent director - Perry Karsen, former Celgene executive, assumes Board Chair role SOUTH SAN FRANCISCO, Calif., December 21, 2020 – Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted DNA integration to treat or cure...
Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease
rajeshl2020-12-21T12:17:12+00:00December 14, 2020 Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease - IND clearance for Phase 1/2 trial establishes Graphite Bio as the first company advancing potentially curative sickle cell gene editing therapy to restore normal hemoglobin expression - GPH101 harnesses the power of CRISPR and natural DNA repair mechanisms...
Graphite Bio Expands Leadership Team with Accomplished Pharmaceutical Executives to Advance Programs to the Clinic and to Achieve Continued Business Growth
rajeshl2020-12-21T12:17:38+00:00November 9, 2020 Graphite Bio Expands Leadership Team with Accomplished Pharmaceutical Executives to Advance Programs to the Clinic and to Achieve Continued Business Growth - Katherine Vega Stultz appointed as chief operating officer - Philip P. Gutry appointed as chief business officer and head of finance & investor relations - Executive hires follow appointment of Dr. Josh Lehrer as chief executive officer SOUTH...
Graphite Bio Launches with $45 Million Series A Financing
rajeshl2020-12-21T12:18:07+00:00Graphite Bio Launches with $45 Million Series A Financing -- Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital -- -- Core technology from Stanford founders Matt Porteus and Maria Grazia Roncarolo -- -- Josh Lehrer joins as CEO – SOUTH SAN FRANCISCO, Calif., September 16, 2020 -- Graphite Bio today announced a $45 million Series A financing...